Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B

British Journal of Pharmacology

Volumn 128, Issue 7, 1999, Pages 1393-1398

  Manning, Carol D ^a   Burman, Miriam ^a   Christensen, Siegfried B ^a   Cieslinski, Lenora B ^a   Essayan, David M ^b   Grous, Marilyn ^a   Torphy, Theodore J ^a   Barnette, Mary S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclic nucleotide phosphodiesterase; Monocytes; PDE4; PDE4 inhibitors; PDE4 subtypes; T lymphocyte proliferation; T lymphocytes; Tumour necrosis factor

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DERMATOPHAGOIDES PTERONYSSINUS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INFLAMMATORY CELL; LYMPHOCYTE PROLIFERATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; T LYMPHOCYTE;

EID: 0032747518     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702911     Document Type: Article

References (35)

1. ALVAREZ, R., SETTE, C., YANG, D., EGLEN, R.M., WILHELM, R., SHELTON, E.R. & CONTI, M. (1995). Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol., 48, 616-622.
2. D). Gene, 138, 253-256.
3. 3H]rolipram binding. Biochem. Pharmacol., 51, 949-956.
4. BARNETTE, M.S., CHRISTENSEN, S.B., UNDERWOOD, D.C. & TORPHY, T.J. (1996b). Phosphodiesterase 4: biological underpinnings for the design of improved inhibitors. Pharmacol. Rev. Comm., 8, 65-73.
5. BARNETTE, M.S., GROUS, M., CIESLINSKI, L.B., BURMAN, M., CHRISTENSEN, S.B. & TORPHY, T.J. (1995a). Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther., 273, 1396-1402.
6. BARNETTE, M.S., MANNING, C.D., CIESLINSKI, L.B., BURMAN, M., CHRISTENSEN, S.B. & TORPHY, T.J. (1995b). The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J. Pharmacol Exp. Ther., 273, 674-679.
7. BOLGER, G., MICHAELI, T., MARTINS, T., St. JOHN, T., STEINER, B., RODGERS, L., RIGGS, M., WIGLER, M. & FERGUSON, K. (1993). A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell. Biol., 13, 6558-6571.
8. CHRISTENSEN, S.B., GUIDER, A.M., FORSTER, C.J., GLEASON, J,G., BENDER, P.E., KARPINSKI, J.M., DeWOLF, W.E.J., BARNETTE, M.S., UNDFRWOOD, D.C., GRISWOLD, D.E., CIELINSKI, L.B., BURMAN, M., BOCHNOWICZ, S., OSBORN, R.R., MANNING, C.D., GROUS, M., HILLEGAS, L.M., BARTUS, J.O., RYAN, M.D., EGGLESTON, D.S., HALTIWANGER, R.C. & TORPHY, T.J. (1998). 1,4,-Cyclohexane carboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J. Med. Chem., 41, 821-835.
9. CONTI, M., JIN, S.L.-C., MONACO, L., REPASKE, D.R. & SWINNEN, J.V. (1991). Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocr. Rev., 12, 218-234.
10. DAVIS, C.W. & DALY, J.W.( 1979). A simple direct assay of 3′,5′-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-boronate affinity gel chromatography. J. Cyclic Nucleotide Res., 5, 65-74.
11. + gene. Proc. Natl. Acad. Sci. U.S.A., 86, 3604-3608.
12. DENT, G., GIEMBYCZ, M.A., RABE, K.F. & BARNES, P.J. (1991). Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulaled respiratory burst by 'type-IV'-selective PDE inhibitors. Br. J. Pharmacol., 103, 1339-1346.
13. ENGELS, P., EICHTEL, K. & LUBBERT, H. (1994). Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett., 350, 291-295.
14. ENGELS, P., SULLIVAN, M., MULLER, T. & LUBBERT, H. (1995). Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett., 358, 305-310.
15. ESSAYAN, D.M., HUANG, S.-K., UNDEM, B.J., KAGEY-SOBOTKA, A. & LICHTENSTEIN, L.M. (1994). Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclcar cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Immunol., 153, 3408-3416.
16. ESSAYAN, D.M., KAGEY-SOBOTKA, S., LICHTENSTEIN, L.M. & HUANG, S.-K. (1997). Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther., 282, 505-512.
17. GANTNER, F., GÖTZ, C., GEKELER, V., SCHUDT, C., WENDEL, A. & HATZELMANN, A. (1998). Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br. J. Pharmacol., 123, 1031-1038.
18. GANTNER, F., TENOR, H., GEKELER, V., SCHUDT, C., WENDEL, A. & HATZELMANN, A. (1997). Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J. Allergy Clin. Immunol., 100, 527-535.
19. HENKEL-TIGGES, J. & DAVIS, R.L. (1989). Rat homologs of the Drosophila dunce gene code for cyclic AMP phosphodiesterase sensitive to rolipram and Ro20-1724. Mol. Pharmacol., 37, 7-10.
20. JACOBITZ, S., MCLAUGHLIN, M.M., LIVI, G.P., BURMAN, M. & TORPHY, T.J. (1996). Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol., 50, 891-899.
21. JIANG, X., PASKIND, M., WELTZIEN, R. & EPSTEIN, P.M. (1998). Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulaled and leukemic human lymphocytes. Cell. Biochem. Biophys., 28, 135-160.
22. MANNING, C.D., MCLAUGHLIN, M.M., LIVI, G.P., CIESLINSKI, L.B., TORPHY, T.J. & BARNETTE, M.S. (1996). Prolonged beta adrenoreceptor stimulation up-regulatcs cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J. Pharmacol. Exp. Ther., 276, 810-818.
23. m, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain: cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J. Biol. Chem., 268, 6470-6476.
24. OBERNOLTE, R., RATZLIFF, J., BAECKER, P.A., DANIELS, D.V., ZUPPAN, P., JARNAGIN, K. & SHELTON, E.R. (1997). Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis. Biochim. Biophys. Acta. 1353, 287-297.
25. PEACHELL, P.T., UNDEM, B.J., SCHLEIMER, R.P., MACGLASHAN, Jr. D.W., LICHTENSTEIN, L.M., CIESLINSKI, L.B. & TORPHY, T.J. (1992). Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol., 148, 2503-2510.
26. SCOTLAND, G., BEARD, M., ERDOGAN, S., HUSTON, E., MCCALLUM, F., MACKENZIE, S.J., PEDEN, A.H., POOLEY, L., RENA, N.G., ROSS, A.H., YARWOOD, S.J, & HOUSLAY, M.D. (1998). Intracellular compartmentalization of PDE4 cyclic AMP-specific phosphodiesterases. Methods 14, 65-79.
27. A1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase. Biochem. J., 308, 673-681.
28. SETTE, C., VICINI, E. & CONTI, M. (1994). The rat PDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem., 269, 18271-18274.
29. SHAKUR, Y., PRYDE, J.G. & HOUSLAY, M.D. (1993). Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem. J., 292, 677-686.
30. SOUNESS, J.E., HOUGHTON, C., SARDAR, N. & WITHNALL, M.T. (1997). Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol., 121, 743-750.
31. SWINNEN, J.V., JOSEPH, D.R. & CONTI, M. (1989). Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc. Natl. Acad. Sci. U.S.A., 86, 5325-5329.
32. THOMPSON, W.J., ROSS, C.P., PLEDGER, W.J., STRADA, S., HANNER, R.L. & HERSH, E.M. (1976). Cyclic adenosine 3′,5′-monophosphate phosphodiesterase: distinct forms in human lymphocytes and monocytes. J. Biol. Chem., 251, 4922-4929.
33. TORPHY, T.J. (1998). Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157, 351-370.
34. TORPHY, T.J., STADEL, J.M., BURMAN, M., CIESLINSKI, L.B., MCLAUGHLIN, M.M., WHITE, J.E. & LIVI, G.P. (1992a). Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem., 267, 1798-1804.
35. TORPHY, T.J., ZHOU, H.-L. & CIESLINSKI, L.B. (1992b). Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exp. Ther., 263, 1195-1205.